1	Evolutionary and phenotypic characterization of spike
2	mutations in a new SARS-CoV-2 Lineage reveals two
3	Variants of Interest
4	Paula Ruiz-Rodriguez ^{1#} , Clara Francés-Gómez ^{1#} , Álvaro Chiner-Oms ² , Mariana G. López ² ,
5	Santiago Jiménez-Serrano ² , Irving Cancino-Muñoz ² , Paula Ruiz-Hueso ³ , Manuela Torres-Puente ² ,
6	Maria Alma Bracho ^{1,4} , Giuseppe D'Auria ^{1,3,4} , Llúcia Martinez-Priego ³ , Manuel Guerreiro ^{5,6} , Marta
7	Montero-Alonso ⁷ , María Dolores Gómez ⁸ , José Luis Piñana ⁹ , SeqCOVID-SPAIN consortium,
8	Fernando González-Candelas ^{1,4} , Iñaki Comas ^{2,4} , Alberto Marina ^{2,10} , Ron Geller ^{1*} , Mireia
9	Coscolla ¹ *
10	1. I ² SysBio, University of Valencia-CSIC, FISABIO Joint Research Unit Infection and Public Health,
11	Valencia, Spain.
12	2. Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
13	3. Sequencing and Bioinformatics Service of FISABIO (Valencian Region Foundation for the
14	Promotion of Health and Biomedical Research), Valencia, Spain.
15	4. CIBER in Epidemiology and Public Health, Spain.
16	5. Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
17	6. Instituto de Investigación Sanitaria La Fe (IIS-La Fe), Valencia, Spain.
18	7. Infectious Diseases Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
19	8. Microbiology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
20	9. Hematology Service, Hospital Clínico Universitario, Institute for Research INCLIVA, Valencia,
21	Spain.

22 10. CIBER in Rare Diseases (CIBERER), Spain.

23 #equal contributions

24 *corresponding author

25 **Keywords:** SARS-CoV-2, Spike, HR2, variants, homoplasy, and antibody escape.

26 Abstract

27 Molecular epidemiology of SARS-CoV-2 aims to monitor the appearance of new variants with 28 the potential to change the virulence or transmissibility of the virus. During the first year of 29 SARS-CoV-2 evolution, numerous variants with possible public health impact have emerged. We 30 have detected two mutations in the Spike protein at amino acid positions 1163 and 1167 that 31 have appeared independently multiple times in different genetic backgrounds, indicating they 32 may increase viral fitness. Interestingly, the majority of these sequences appear in transmission 33 clusters, with the genotype encoding mutations at both positions increasing in frequency more 34 than single-site mutants. This genetic outcome that we denote as Lineage B.1.177.637, belongs 35 to clade 20E and includes 12 additional single nucleotide polymorphisms but no deletions with 36 respect to the reference genome (first sequence in Wuhan). B.1.177.637 appeared after the first 37 wave of the epidemic in Spain, and subsequently spread to eight additional countries, increasing 38 in frequency among sequences in public databases. Positions 1163 and 1167 of the Spike protein 39 are situated in the HR2 domain, which is implicated in the fusion of the host and viral 40 membranes. To better understand the effect of these mutations on the virus, we examined 41 whether B.1.177.637 altered infectivity, thermal stability, or antibody sensitivity. Unexpectedly, 42 we observed reduced infectivity of this variant relative to the ancestral 20E variant in vitro while 43 the levels of viral RNA in nasopharyngeal swabs did not vary significantly. In addition, we found the mutations do not impact thermal stability or antibody susceptibility in vaccinated individuals 44 45 but display a moderate reduction in sensitivity to neutralization by convalescent sera from early

46 stages of the pandemic. Altogether, this lineage could be considered a Variant of Interest (VOI), 47 we denote VOI1163.7. Finally, we detected a sub-cluster of sequences within VOI1163.7 that 48 have acquired two additional changes previously associated with antibody escape and it could 49 be identified as VOI1163.7.V2. Overall, we have detected the spread of a new Spike variant that 50 may be advantageous to the virus and whose continuous transmission poses risks by the 51 acquisition of additional mutations that could affect pre-existing immunity.

52 Introduction

53 Genomic surveillance of viral mutations is the first step in detecting viral changes that could 54 impact public health by interfering with diagnostics, modifying pathogenicity, or altering 55 susceptibility to existing immunity or treatments. In many countries, the challenge of detecting 56 new mutations of interest in SARS-CoV-2 is approached by sequencing representative genomes 57 from circulating viruses, sharing sequence information on public databases (e.g. GISAID¹), and 58 analysing them in real-time using platforms, such as Nextstrain². While mutations appear 59 randomly, their fate in the population depends on a combination of the conferred fitness 60 advantage as well as stochastic and demographic processes. A first step in assessing the 61 potential public health impact of mutations is to decipher if their increase in frequency is due to chance or adaptation. If found to be adaptive, it is important to evaluate whether their 62 63 adaptation is linked to an improved ability to replicate, colonize, transmit, or evade antiviral 64 hosts defences³. An important challenge in the field is to decipher which of all the variants that 65 appear should be monitored to implement measures to mitigate their risk to public health. 66 Genotypes that are phenotypically different from a reference isolate or have mutations that lead 67 to changes associated with either established or suspected phenotypes could be considered Variants of Interest (VOI) if they also fit one of the following criteria: i) cause community 68 69 transmission/multiple COVID-19 clusters or ii) have been detected in multiple countries⁴. Among 70 VOI, only those genotypes that are associated with higher transmissibility, with detrimental

changes in COVID-19 epidemiology, with increased virulence, with changes to clinical
 presentation, or with decrease effectiveness of public health measures, diagnostics, vaccines or
 therapeutics are further categorized as variants of concern⁴.

74 Mutations in SARS-CoV-2 have been reported since the early stages of the epidemic⁵⁻⁷. While no 75 signs of recombination have been detected so far among SARS-CoV-2 variants⁸, the most 76 common mutations described are single nucleotide polymorphisms (SNPs) and small deletions⁹⁻ 77 ¹¹. Genomic surveillance of mutations has been mostly focused on the Spike (S) protein because 78 of its key roles in viral entry and immunity¹², as well as the fact that this protein constitutes the 79 basis of numerous SARS-CoV-2 vaccines¹³. S is a homotrimeric protein, whose heavily 80 glycosylated ectodomain protrudes from the viral membrane, showing a bat-like shape with a 81 N-terminal globular head portion connected to the membrane by an elongated stalk¹⁴. The S 82 protein is proteolytically processed by the cellular furin protease into the S1 and S2 subunits^{15,16}. 83 Additional proteolytic cleavage occurs following S protein binding to the host receptors, 84 facilitating S1 subunit release. The C-terminal S2 subunit remains trimeric in the viral membrane 85 but undergoes conformational changes that promote viral membrane fusion with the host cell¹⁷. 86 A key role in these conformational changes is played by two heptad repeat motifs, HR1 and HR2 87 that, starting from the head and stalk regions in the pre-fusion state of S protein, form a HR1-HR2 six-helix bundle in the post-fusion state that is critical for viral entry¹⁸. 88

The first mutation that was identified as of potential concern was an aspartic acid to a glycine mutation in the S1 subunit of the S protein at position 614 (D614G). D614G emerged early in the epidemic, became predominant in most countries within 2 months, and completely dominated the epidemic by August 2020¹⁹. As with any mutant, the initial spread of this mutation could have resulted from stochastic events, the dynamics of epidemic, or an intrinsically higher viral fitness. More than six months after the initial report of this mutation, several studies have found evidence in favour of higher transmission efficacy in animal models and human populations^{5,20-}

²². This variant replicates better in some cell culture and animal models^{20,21,23}, and is associated
with higher viral loads in infected individuals¹⁹; importantly, however, it does not impact
diagnostics or vaccine efficacy.

99 Following the first wave of the pandemic, additional variants have been reported from many 100 countries. Among the first of these was the A222V mutation at the N-terminal domain (NTD) of 101 the S1 subunit, which occurred in the background of the D614G S protein mutation. This variant, 102 termed 20E, was first sequenced in Spain and expanded throughout Europe⁶. Other variants 103 have been reported since, such as the so-called "cluster 5", which harbours a combination of 3 104 SNPs and single deletion related to mink farms in Denmark²⁴. One of the SNPs is in the S protein 105 of this variant, Y453F, occurs in the receptor binding domain (RBD) and may increase binding to 106 cell receptors in mink²⁵. Transmission of this variant between humans and minks has been 107 reported⁷, highlighting a possible risk of expansion in the human population, which resulted in 108 proposals for large scale culling of mink populations in Denmark. Studies to assess the biological 109 impact of this mutant have not been reported but there is no evidence for its wide spread over the course of >6 months since its description²⁶. By December 2020, three variants of concern 110 111 (VOCs) were described, all of which share the N501Y amino acid replacement in the RBD of the S protein: 20I/501Y.V1 (also called Lineage B.1.1.7) was originally described in the UK¹¹, 112 113 20H/501Y.V2 (B.1.351) in South Africa, and 20J/501Y.V3 (P1) in Brazil. These variants are of particular concern because they are more transmissible²⁷⁻²⁹ and, although data on antigenicity 114 115 and disease severity is not conclusive, could result in reduced susceptibility to neutralization by existing immunity and affect vaccine efficacy³⁰⁻³³. Importantly, all of these variants have spread 116 117 outside of the country where they were initially identified and are estimated to spread faster than other co-circulating genotypes^{27,34,35}. 118

In this work, we have performed a detailed phylogenomic analysis of the appearance, spread
and evolution of two mutations involving amino acid positions 1163 and 1167 of the HR2

functional motif of S protein. Our results provide evidence of repeated, independent emergence, suggesting these mutations contribute to increased viral fitness. In addition, we have evaluated the biological relevance of these mutations to viral infectivity, virion stability, and neutralization by sera from convalescent and vaccinated individuals.

125 **Results**

126 Multiple and independent mutations in amino acid positions 1163 and 1167 of the Spike 127 protein.

128 SARS-CoV-2 genetic variation has been monitored by the Spanish sequencing consortium 129 SeqCOVID to follow the expansion of mutations that could potentially result in a change of the 130 biological properties of the virus. We focused on mutations in the S protein because of its 131 relevance for infection and immunity¹². We detected two mutations in the *spike* gene: G25049T 132 (D1163Y) and G25062T (G1167V), which appeared in Spain as early as March and April 2020, 133 respectively (Supplementary Fig.1). These mutations continued arising independently of each 134 other and, by the end of June, when the predominant circulating genotypes from the first wave 135 in Spain had already been replaced by other variants³⁶, were also observed together 136 (Supplementary Fig.1). Both positions have mutated multiple times independently and to 137 different amino acids at a lower frequency. On the one hand, D1163 appears mutated at least 138 99 times (D1163Y: 84, D1163V: 4, D1163G: 3, D1163A: 2, D1163E: 2, D1163H: 2, D1163N: 1, and 139 D1163H/Y: 1) in 47 lineages according to the PANGO scheme³⁷. On the other hand, G1167 140 appears mutated at least 54 times (G1167V: 39, G1167D: 4, G1167C: 3, G1167R: 3, G1167S: 3, 141 G1167F: 1, and G1167A: 1) in 20 PANGO lineages including B.1 (Supplementary Fig.2e) and its 142 derivatives B.26, B.40 (Supplementary Fig.2c), and D.2 (Supplementary Fig.2f).

143 Clusters of transmission with amino acid changes in positions 1163 and 1167 of Spike

144 Positions 1163 and 1167 in the S protein have mutated independently multiple times in SARS-145 CoV-2. The majority of mutated sequences (94.43%) were found in transmission clusters (see 146 methods for definition of clusters; Figure 1a,b), with a small minority not belonging to a 147 transmission cluster due to either incomplete sampling or failure to spread. While different 148 amino acids changes have been detected at both positions, only one change at each position appeared in most clusters: D1163Y in 83.33% and G1167V in 69.23% clusters. D1163Y appeared 149 150 in 22 transmission clusters (Figure 1a) and G1167V in 8 clusters (Figure 1b). Interestingly, the 151 biggest cluster included both the D1163Y and G1167V mutations together. We denote this 152 cluster as B.1.177.637, which was detected in 65 sequences from Spain until December 2020, 153 representing 1.17% of the Spanish sequences. Globally, this cluster, which is within lineage 20E (also described as 20A.EU1⁶, and B.1.177³⁷), includes 1,627 sequences (Figure 1c). B.1.177.637 154 155 is characterized by nine nonsynonymous and six synonymous mutations with respect to the 156 reference sequence from Wuhan (Supplementary table 2), but no deletions were shared among 157 B.1.177.637 sequences. Amino acid changes were found in A222V, D614G, D1163Y, and G1167V 158 in the S protein, A220V and P365S in the N protein, V30L in ORF10, L67F in ORF14, and P4715L 159 in ORF1ab (Supplementary Fig.3 and Supplementary table 2). Synonymous mutations were also 160 observed in the orf1ab, n and m genes (Supplementary Fig.3 and Supplementary table 2). All 161 evidence support we consider this cluster a new Lineage, and we requested to be under the 162 name B.1.177.637 (https://github.com/cov-lineages/pango-designation/issues/22).





164 Figure 1. Sequences mutated at positions 1163 and 1167 of the S protein. a. The number of 165 mutation events for amino acid replacement D1163Y (light orange) or another D1163 amino acid 166 replacements (dark orange). b. The number of mutation events for amino acid replacement 167 G1167V (light turquoise) or another G1167 amino acid replacements (dark turquoise). Bars 168 coloured in magenta indicate the appearance of both the D1163Y and G1167V amino acid 169 replacements in the same sequences. c. Maximum-likelihood phylogeny of 10,450 SARS-CoV-2 170 genomes. The inner circle of the rings represents sequences with amino acid changes in position 171 D1163 of the S protein. The external circle represents sequences with amino acid changes in 172 position G1167 of the S protein. Branches are coloured in magenta for B.1.177.637, green for 173 clade 20E, and orange for cluster 1163.654. The scale bar indicates the number of nucleotide 174 substitutions per site. d. Temporal distribution and frequency of sequences with variant 175 B.1.177.637 coloured by geographical origin.

Within 20E, the second largest cluster including any of these mutations was observed in 34 sequences with E654Q and D1163Y in S protein plus 7 nonsynonymous and 6 synonymous mutations (Supplementary table 2 and Supplementary Fig.3). We denote this second cluster, which is also embedded within lineage 20E, cluster 1163.654 (Figures 1c and S3). Cluster 1163.654 appeared first in Ireland on 2020-07-23 and subsequently appeared in Spain and England. However, after three months, cluster 1163.654 is no longer being detected. A large cluster within Lineage 20E is formed by 37 sequences with the mutation G1167F. Sequences for this cluster were obtained in Wales between the end of October and the beginning of November 2020 (dark pink in the external circle in Supplementary Fig.2g).

185

186 We found additional clusters involving mutations in position 1163 of the S protein; the largest 187 cluster is composed of 64 sequences within Lineage B.1. The majority of which are from 188 Denmark but also includes sequences from England and Sweden (orange in external ring in 189 Supplementary Fig.2e). Among other smaller clusters, a cluster of 10 sequences with G1167V 190 (within Lineage B.1) appeared in Spain in March (indicated in cyan within the external circle of 191 Supplementary Fig.2e). The cluster was detected in two regions in Spain (Valencia, and Galicia), 192 but was controlled with lockdown measures imposed in Spain from March to May and was not 193 detected after May 2020. The same mutation was found in a cluster of 28 sequences within 20E 194 from England and Wales between October and November 2020 (indicated in cyan within the 195 external circle of Supplementary Fig.2g). Similarly, another cluster of 11 sequences in Lineage 196 B.1.1 and with the mutation G1167A was detected in early January 2021, encompassing 197 sequences from Ecuador, Colombia, and Peru (Supplementary Fig.2f). Within Lineage B.53, we 198 found a cluster of 12 sequences from Lithuania with mutation D1163Y. Finally, we found small 199 clusters with mutations in 1163 or 1167 within Lineage B.40 and Lineage A (Supplementary 200 Fig.2b, c).

Because of the risk posed by VOC^{11,26,35}, we examined whether mutations in 1163 and 1167 of the S protein were observed in the three VOC described to date. Indeed, mutations in these two positions were observed in two VOC, 20I/501Y.V1 and 20H/501Y.V2. Mutations involving amino acid positions 1163 and 1167 appeared independently in the background of 20I/501Y.V1 multiple times. Specifically, mutations in D1163 have occurred at least 13 times in 24 sequences,

including four transmission clusters and nine unique sequences (Supplementary Fig.4), while
mutations at G1167 were observed in at least five independent sequences. Interestingly,
D1163Y and G1167V were observed together in only one individual within 20I/501Y.V1,
although they were not fixed (relative frequency of 27% and 17% of the reads with D1163Y and
G1167V, respectively; Supplementary table 3). Finally, only two sequences that harbour the
amino acid replacement G1167V in the S protein were observed in the genomic background
20H/501Y.V2 (Supplementary table 3).

213 Evolution of B.1.177.637

214 We explored the emergence and evolution of B.1.177.637, the largest and most successful 215 cluster involving amino acid changes in positions 1163 and 1167 of the S protein. Lineage 216 B.1.177.637 appeared in Spain in June 2020 in sequences from the Basque Country (Figure 1d, 217 and Supplementary Video 1) and subsequently appeared in individuals from other countries, 218 comprising a total of 1,627 sequences in GISAID (0.60% of 270,869 analysed sequences by 23rd 219 of December 2020) (Figure 1d and Supplementary Video 1). The majority of the B.1.177.637 220 sequences were obtained from the United Kingdom, including England (1,058), Scotland (419), 221 Wales (34) and Northern Ireland (5), but were also observed in Gibraltar (24 sequences), 222 indicating successful migration and transmission (Supplementary Video 1). Although 223 B.1.177.637 is not well represented in sequences from other countries, it has been found in 224 multiple sequences from Denmark (9), Switzerland (8), Norway (2), and single sequences from 225 Italy, France, Singapore, and Ireland. By the end of 2020, B.1.177.637 was still circulating in 226 Europe (Figure 1d and Supplementary Video 1), and by the end of February 2021 it was 227 represented by 1,923 sequences in GISAID (0.33% of submitted sequences).

Within B.1.177.637, we detected additional SNPs in individual sequences or small groups of sequences. One of these changes is E484K in the RDB of the S protein, a mutation present in three VOCs (20I/501Y.V1, 20H/501Y.V2 and 20J/501Y.V3) that is implicated in increased ACE2

binding³⁸ and reduced neutralization by antibodies³⁹. In addition, we found another change 231 associated with evasion of antibody immunity: a deletion of positions 141-144 in the S protein, 232 which partially overlaps with a smaller deletion at 144 reported in VOC 20I/501Y.V1⁴⁰. This sub-233 234 cluster included five sequences along January 2021 from England and Wales (Supplementary 235 table 2). The five sequences formed a monophyletic group embedded in B.1.177.637 (Supplementary Fig.5), identified as cluster B.1.177.637.V2, which displays other 236 237 nonsynonymous and synonymous mutations (Supplementary table 2) and only two sites are 238 polymorphic within B.1.177.637.V2.

239 Positions 1163 and 1167 of the S protein are located in the heptad repeat 2 motif

240 The S protein mediates both the binding to cellular receptors and entry into the host cells¹². For 241 the former, the RBD motif in the S1 subunit interacts with the cellular receptor in the pre-fusion 242 state. In the post-fusion state, two heptads repeat sequences (HR1 and HR2) in the S2 subunit 243 must form a six-helix bundle in order to bring the viral and cellular membrane into close 244 proximity^{41,42} (Figure 2). S protein positions 1163 and 1167 are both located within the HR2 245 domain. Specifically, 1167 is present at the beginning of the HR2 motif and 1163 in its upstream 246 linker region (Figure 2a). Interestingly, this motif is highly invariable, showing 100% conservation across 14 related sarbecoviruses to which SARS-CoV-2 belongs to (Supplementary table 1)^{43,44}. 247 248 Structural characterization of full-length ectodomain of S protein has shown that the stalk 249 portion encompassing positions 1163 and 1167 presents intrinsic flexibility in the pre-fusion state¹⁸, precluding its atomic visualization. This has been recently confirmed by high-resolution 250 251 cryo-electron tomographic reconstitution of SARS-CoV-2¹⁴, where this region was observed to 252 constitute a flexible hinge that acts as a "knee", connecting two helical coiled-coil regions of the 253 stalk (upper and lower legs; Figure 2b). Within this structure, the conformational freedom 254 provided by the glycine residue at position 1163 should play a key role in the flexibility of the 255 knee. In contrast, in the post-fusion state, this region shows high rigidity due to a strong

256 structural rearrangement of the HR2 motif, which adopts an extended conformation and tightly 257 packs along the central 3-helix bundle stem formed by the HR1 motif (Figure 2c). The resulting 258 HR1-HR2 bundle plays a key role in the mechanism of viral-host membrane fusion^{18,45} and 259 mutations in this region could have significant impact on the function of the S protein. In 260 addition, the HR2 region is highly glycosylated, which is observed to be regularly spaced in both 261 the pre- and post-fusion states and to mostly align to the side of the helix bundle^{14,18,45}. Of note, 262 two of these branched sugars are placed at positions N1158 and N1173, hiding positions 1163 263 and 1167 (Figure 2b). Therefore, changes in stalk flexibility might have relevance in immunity by 264 influencing both the intrinsic degree of exposure of this region and its sugar shielding.

265 Using the available structural information of the S protein in the pre- and post-fusion 266 conformations¹⁸, we examined the possible implications of these mutations to viral infectivity. 267 Based on these structures, G1167V mutation is predicted to confer significant rigidity to the 268 structure in two ways. First, the introduction of a side chain strongly reduces the conformational 269 freedom provided by the glycine residue. Second, the presence of the new aliphatic side chain 270 provided by the valine residue strongly increases hydrophobicity, likely promoting the burial of 271 this side chain in the HR1 helix 3-bundle stem in the post-fusion state or favouring its integration 272 in the neighbour helical coiled-coil in the pre-fusion state (Figure 2b,c). Unlike position 1163, 273 position 1167 is fully exposed to the solvent in both the pre- and post-fusion states (Figure 2b,c). 274 Hence, the effect of D1163Y is likely to stem a change in nature of the side chain, switching from 275 a charged aspartic acid residue at physiological pH to a polar group with hydrophobic properties 276 in the tyrosine.



278 Figure 2. The structure of 1163 and 1167 in the pre and post-fusion states of S protein. a. 279 Schematic representation of the S protein. SP. Signal peptide; NTD, N-terminal domain; RBD, 280 receptor-binding domain; SD1-2, subdomains 1 and 2; L-UH, Linker-Upstream helix; FP, fusion 281 peptide; CR, connecting region; HR1, heptad repeat 1; CH-SD3, central helix subdomain 3; BH, 282 β -hairpin; HR2, heptad repeat 2; TM, transmembrane; CD, cytoplasmic domain. Mutations 283 D1163Y and G1167V are indicated in purple and other mutations described in the text in green. 284 b. Cartoon representation (left) of a structural model of pre-fusion membrane-bound trimeric S protein⁴⁶. In each subunit the RBD, HR1 and HR2 domains are coloured in different tones (light 285 286 to dark) of blue, yellow, and green. The N-glycosylation of N1155 and N1176 are shown in stick 287 representation and coloured as the corresponding subunit. Functional and structural regions are 288 marked. A close-view (right) of the N-terminal portion of HR2 where D1163Y and G1167V 289 mutations are found. The side-chains of mutated and hydrophobic residues in the HR2 region 290 are shown in stick representation and coloured as corresponding subunit (mutated residues in 291 lighter tone). c. Cartoon representation (left) of S2 subunit in post-fusion conformation with HR1

and HR2 regions coloured as in b and N-glycosylation around mutation position shown as sticks.
A close-view of the region encompassing the mutations (right), showing in stick representation
the mutated and hydrophobic residues from the HR2 region shown in panel b. Dotted lines
highlight HR2 disordered regions in the Cryo-EM structure.

296 Spike aminoacid changes D1163Y and G1167V do not increase viral infectivity

297 Previous reports have indicated that mutations in the S protein can increase infectivity^{5,21,47-49}. 298 Because the highest transmission success for mutations in S positions 1163 and 1167 299 corresponds to the double mutant D1163Y and G1167V (characteristic of B.1.177.637), we 300 explored whether these mutations in combination have an influence on infectivity. For this, we 301 pseudotyped vesicular stomatitis virus lacking its glycoprotein and encoding GFP⁵⁰ (VSVΔG-GFP) 302 with different S genotypes: Wuhan (D614), D614G, 20E (A222V and D614G), or B.1.177.637 303 (A222V, D614G, D1163Y and G1167V). Infectious virus production was then assessed by limiting 304 dilution and counting of GFP-positive cells in both Vero cells and A549 human alveolar basal 305 epithelial cells expressing human ACE2 and TMPRSS2 (A549-hACE2-TMPRSS2). As previously 306 reported^{19,21,51}, the 20E S genotype enhanced infectivity relative to the Wuhan S genotype by 307 70% in both Vero (p-value = 0.005 by unpaired t-test; Figure 3a) and A549-hACE2-TMPRSS2 cells 308 (p-value = 0.016 by unpaired t-test; Figure 3b). The 20E S genotype also showed a trend towards 309 increased infectivity versus the D614G mutation alone (35% increase in both cell lines), as has 310 been previously reported⁴⁹, yet the difference was not statistically significant (p-value > 0.05 by 311 unpaired t-test; Figure 3a,b). In contrast, B.1.177.637 S genotype significantly diminished virus 312 infectivity versus the 20E genotype, reducing virus titers by 20% in Vero cells (p-value = 0.009 by 313 unpaired t-test; Figure 3a) and 29% in A549-hACE2-TMPRSS2 (p-value = 0.03 by unpaired t-test; 314 Figure 3b). This is in agreement with a potential stabilization of the HR2 helix (Figure 2), which 315 should limit the ability of the S protein to sample different structural conformations that could

be required for binding host-cell receptors. Hence, B.1.177.637 S genotype does not increase

317 infectivity *in vitro*.



319 Figure 3. Comparison of the infectivity and stability of different S genotypes. a, b. The 320 infectivity of VSV particles pseudotyped with each S protein genotype in either Vero (a) or 321 human A549 cells expressing ACE2 and TMPRSS2 (b). The mean and standard deviation of three 322 replicates is plotted. c. Comparison of cycle threshold (Ct) values for the n gene from patients 323 infected with viruses encoding different S protein variants. Data is derived from 2,534 sequences 324 from SeqCOVID consortium. The number of observations (N) analysed for each genotype is 325 indicated. d. The thermal sensitivity of VSV pseudotyped with different S genotypes following 326 incubation at 15 minutes. Data are standardized to the surviving fraction following incubation 327 at 30°C, and the three-parameter log-logistic equation is plotted. FFU: focus forming units.

328 To examine whether reduced infectivity could also be observed in vivo, we tested if individuals 329 infected with B.1.177.637 have different viral loads. For this, we used the cycle threshold (Ct) of real-time PCR used for diagnosis as a surrogate. As previously reported¹⁹, we detected higher Ct 330 331 values for D614 wild-type variant (Ct mean = 27.00) compared to genotypes encoding the D614G 332 S protein mutation (Ct mean = 25.32; p-value < 0.01 by unpaired Wilcoxon test, Figure 3c). 333 However, we did not find significant differences in viral loads between individuals infected with 334 B.1.177.637 genotype and other genotypes within 20E (Ct mean = 21.14 vs Ct mean = 20.63, p-335 value = 0.72 by unpaired Wilcoxon test, Figure 3c). Interestingly, higher viral loads were 336 observed in individuals infected with B.1.177.637 and others 20E (D614G and A222V) compared 337 to the D614G alone (D614G Ct mean = 25.32, 20E Ct mean = 21.14, B.1.177.637 Ct mean = 20.63, 338 p-value < 0.01 for both comparisons by unpaired Wilcoxon test, Figure 3c). This data suggests 339 that, unlike the results of the in vitro studies, B.1.177.637 replicates as efficiently as other 20E 340 genotypes in vivo, although mutations outside of the S protein could contribute to this result.

341 Amino acid changes D1163Y and G1167V do not alter S protein stability

As increased S protein stability could impact transmissibility by maintaining virion infectivity during the intra-host transmission period, we assessed the temperature sensitivity of the 344 different S variants. For this, we subjected VSV particles pseudotyped with different S genotypes 345 to a range of temperatures for 15 minutes, after which we evaluated the surviving fraction. 346 Overall, no major differences in the degree to which the different S proteins lost infectivity upon 347 heat exposure were observed, with all S proteins showing a 50% reduction in infectivity at a 348 similar temperature range (39.8-42.2°C; p-value > 0.05 for all except Wuhan S genotype (D614) 349 versus 20E S genotype (A222V and D614G), where p-value = 0.01; Figure 3d). Hence, the D1163Y 350 and G1167V mutations do not seem to have a major impact in the thermal stability of the S 351 protein.

Spike D1163Y and G1167V modestly reduce sensitivity to neutralization by existing antibody immunity

354 Positions 1163 and 1167 of the S protein have been reported to occur in both T and B cell SARS-CoV-2 epitopes⁵²⁻⁵⁴. Moreover, numerous studies have shown that mutations in the S protein 355 356 can affect antibody neutralization^{30,31}. We therefore examined if the presence of D1163Y and 357 G1167V alters the neutralization capacity of convalescent sera using VSV pseudotyped with 358 either the 20E or B.1.177.637 S genotypes. In order to capture the potential influence of 359 different infecting variants on antibody neutralization, we tested the sensitivity of these 360 pseudotyped viruses to neutralization by sera from early (April 2020; First wave in Spain) or later 361 (October 2020; Second wave in Spain) in the pandemic, when newer variants were dominant^{6,36}. 362 Overall, B.1.177.637 genotype conferred a modest but statistically significant reduction in 363 sensitivity to neutralization by six serum samples tested from the early stage of the pandemic, 364 as measured by the titers required to inhibit viral entry by 80% (ID₈₀; mean = 6.75, range: 1.30-365 17.68; p-value = 0.008 by paired t-test; Figure 4a). A statistically significant but smaller effect 366 was observed when the titers required to inhibit viral entry by 50% were examined (ID₅₀; mean 367 = 2.27, range: 1.61-3.54; p-value < 0.001 by paired t-test; Supplementary Fig.6). In contrast, both 368 20E and B.1.177.637 were equally susceptible to sera from patients infected during the second

369 wave (ID₈₀; mean = 1.03, range: 0.87-1.23; p-value = 0.83 by paired t-test; Figure 4b). These 370 results indicate that the D1163Y and G1167V mutations can provide some degree of escape from 371 pre-existing antibody-based immunity relative to the 20E S genotype depending on the genomic 372 background of the infecting genotype. As a modest reduction in titers was observed with sera 373 from early in the pandemic (Figure 4a), which is more closely related to the current S genotype present in approved vaccines^{55,56}, we examined if B.1.177.637 S genotype resulted in reduced 374 375 neutralization by sera from donors vaccinated with the BNT162b2 vaccine. No significant 376 differences in susceptibility to antibody neutralization from vaccinated donors were observed 377 between the two genotypes, indicating that VOI1163.7 is unlikely to alter the efficacy of vaccines 378 based on the Wuhan S genotype (Figure 4c).



Figure 5. Antibody neutralization of 20E and B.1.177.637 variants. The reciprocal titer at which infection with the 20E S genotype (A222V and D614G) or B.1.177.637 S genotype (20E plus D1163Y and G1167V) is reduced by 80% (ID₈₀) by sera from individuals infected during the early stage of the pandemic in (a) or during a later stage of the pandemic (b) or from donors vaccinated with the BNT162b2 vaccine (c). The mean and standard error of three replicates is plotted.

386 **Discussion**

387 SARS-CoV-2 success is linked to its ability to infect and be transmitted. Mutations that emerge 388 independently several times and increase in frequency are likely to confer enhanced viral 389 infectivity, transmission, or immune evasion. The identification of such mutants is of great 390 importance, as they can significantly impact public health. In this work, we have identified two 391 mutations in the S protein that are likely to be beneficial for the virus based on several lines of 392 evidence. First, these mutations are highly variable within SARS-CoV-2 but conserved across the 393 closely related coronaviruses. Second, the vast majority of sequences harbouring these 394 mutations appear in clusters (Figure 1a and 1b). Third, the largest cluster, and therefore the 395 most successful in terms of transmission, includes both mutations together (Figure 1a and 1b). 396 Additionally, both positions have been reported as positively selected multiple times throughout 397 the SARS-CoV-2 phylogeny indicating a fitness advantage⁵⁷. Although either mutation in 398 isolation could be advantageous, their co-occurrence in a large cluster that has been sustained 399 for more than six months across Europe is suggestive of increased fitness when both mutations 400 are present together.

Positions 1163 and 1167 are found in the HR2 domain of the S protein, adjacent to the transmembrane domain. Examination of available structural data suggests that G1167V might alter the flexibility of the S protein stalk by both restricting the conformational freedom normally conferred by the glycine residue and by introducing a hydrophobic side chain that will favour

405 burial in the HR2 coiled-coil leucine zipper of the pre-fusion state (Figure 2). This extensive 406 flexibility of S prefusion stalk seems to be unique to the SARS-CoV-2 S protein and has not been 407 reported for other class I fusion proteins¹⁸. The stalk flexibility has been suggested to increase 408 avidity for the host receptors by allowing the engagement of multiple S proteins¹⁸. Therefore, 409 stalk stabilization is likely to result in a reduced ability of S to bind receptors in the target cell. 410 Indeed, we find the B.1.177.637 genotype to have reduced infectivity compared to the 20E 411 genotype in both Vero and A549-hACE2-TMPRSS2 cells (Figure 3a, b). In contrast, viral load in 412 individuals infected with different S genotypes indicated that 20E and B.1.177.637 reach similar 413 degrees of viral replication in vivo (Figure 3c). This apparent discrepancy in the effect of the two 414 mutations on infectivity may stem from the differences of SARS-CoV-2 infection in vivo and in 415 the in vitro assay. A recent publication has suggested that the tyrosine-protein kinase receptor 416 UFO (AXL) is an important mediator of SARS-CoV-2 entry and may be of higher relevance for 417 infection of the lung than ACE2⁵⁸. The effect of entry via AXL in the two cell lines used may be 418 overshadowed by high levels of ACE2 expression. Alternatively, additional factors could underlie 419 this difference, including the presence of additional mutations outside of the S protein or 420 differences of viral loads across sampling times in vivo during the infection.

Increased temperature stability can potentially confer a fitness advantage to the virus by reducing losses to infectivity during environmental transition between hosts. Hence, we also examined whether these mutations altered the temperature stability of the virions. Overall, no major difference in stability was observed between VSV pseudoparticles bearing the D614, D614G, 20E, or B.1.177.637 S protein genotypes (Figure 3d). Hence, changes in protein stability are unlikely to underlie the increased transmission of these variants.

Finally, as the S protein is a major target of the immune response¹², immune evasion represents
one possible consequence of mutations in this protein. Both S positions 1163 and 1167 are
embedded in experimentally confirmed T cell and B cell epitopes. For T cell epitopes, a predicted

430 HLA-II epitopes including position 1163 and 1167 has been experimentally verified to bind to 431 HLA DRB1*01:01, the prototype molecule for the DR supertype (epitope identifier in Immune 432 Epitope Data Base: 9006⁵⁹). Additionally, D1163 is included in a SARS-CoV-2 T cell epitope 433 eliciting T-cell responses in convalescent COVID-19 cases⁶⁰ as well as in SARS-CoV-2-naïve individuals⁵³, indicating cross-reactivity in epitopes involving these regions. B cell linear epitopes 434 that span D1163 and G1167 have also been reported⁵², with D1163 belonging to a dominant 435 linear B cell epitope recognized by more than 40% COVID-19 patients used in the assay⁵⁴. D1163 436 is fully solvent exposed in available structure^{18,45}, making its side-chain easily accessible to 437 438 antibodies, providing a potential mechanism for altering antibody binding. To directly examine 439 whether the mutated S positions 1163 and 1167 influence susceptibility to pre-existing humoral 440 immunity, we examined the neutralization capacity of convalescent sera against the 20E variant 441 or B.1.177.637. For this, we used sera from both the first (April 2020) and second (October 2020) 442 waves of the infection in Spain, because an almost complete replacement of SARS-CoV-2 S 443 variants occurred between these two times of the pandemic in Spain³⁶. When utilizing sera from 444 donors infected during the first wave of the pandemic in Spain, we found a modest but 445 statistically significant reduction in susceptibility to neutralization of the B.1.177.637 S genotype 446 compared to the 20E S genotype of approximately 6-fold (Figure 4a). However, no difference in 447 neutralization was observed between the two variants when sera from patients infected during 448 the second wave was used (Figure 4b), highlighting variant-specific differences in antibody 449 responses. Overall, the magnitude of the observed reduction in neutralization susceptibility to 450 sera from individuals infected during the first wave was much less pronounced than that observed for other genotypes implicated in immune evasion³¹. Nevertheless, the degree of 451 452 reduced neutralization required to confer a biologically relevant fitness advantage in vivo has 453 not been established, and even relatively small reductions in susceptibility to antibody 454 neutralizations could potentially confer a significant advantage to replication. Indeed, this has 455 been suggested to be the case in an immunosuppressed individual treated with convalescent

456 serum, where mutations selected during the course of treatment conferred a similar reduction
457 to that observed in the current study⁶¹. Finally, no evidence was found for reduced neutralization
458 by sera from donors immunized with the BNT162b2 vaccine (Figure 4c), which is based on the
459 Wuhan S genotype, indicating antibody immunity elicited by Pfizer-BioNTech COVID-19 vaccine
460 (BNT162b2; February 2021) would not be affected by amino acid replacements in 1163 and 1167
461 sites in S protein.

Although further experiments are needed to decipher the mechanisms by which the two S 462 463 mutations identified could confer a selective advantage to the virus, the evidence presented 464 supports B.1.177.637 as a VOI (VOI1163.7.V1) according to recently published criteria⁴. First, 465 amino acid replacements in S protein: D1163Y and G1167V lead to changes associated with 466 suspected phenotypic change because of the rigidity it poses to the S protein. Second, the 467 genotype showed moderate but significantly lower antibody susceptibility compared to 20E S 468 genotype. And third, it has been identified to cause community transmission, appearing in 469 multiple COVID-19 cases, and detected in multiple countries. Additionally, a subgroup within 470 B.1.177.637 (denoted as VOI1163.7.V2) includes two additional mutations leading to amino acid changes in S with established phenotypic impact on humoral immunity: E484K⁶² and 141-471 472 144Del^{40,63}.

Whether VOI1163.7.V1 and VOI1163.7.V2 will continue to increase in frequency and accumulate additional mutations that could improve its fitness and/or present challenges to vaccines or diagnostics remains to be seen. However, their characterization as VOI would help to discover if enough evidence holds to consider them VOC and therefore required monitoring.

477 Methods

478 Whole-genome sequencing and genome assembly of SeqCOVID consortium sequences

A total of 5,017 clinical samples were received, sequenced, and analysed by the SeqCOVID consortium from all autonomous communities of Spain. These samples were confirmed as SARS-CoV-2 positive by RT-PCR carried out by Clinical Microbiology Services from each hospital. Sequencing of the samples has been approved by the ethics committee: Comité Ético de Investigación de Salud Pública y Centro Superior de Investigación en Salud Pública (CEI DGSP-CSISP) Nº 20200414/05. All sequences are available at GISAID under the accession numbers detailed in Supplementary table 4.

For sequencing, RNA samples were retro-transcribed into cDNA. SARS-CoV-2 complete genome amplification was performed in two multiplex PCR, according to the protocol developed by the ARTIC network⁶⁴, using the V3 multiplex primers scheme⁶⁵. From this step, two amplicon pools were prepared, combined, and used for library preparation. The genomic libraries were constructed with the Nextera DNA Flex Sample Preparation kit (Illumina Inc., San Diego, CA) according to the manufacturer's protocol, with 5 cycles for indexing PCR. Whole-genome sequencing was performed in the MiSeq platform (2×200 cycles paired-end run; Illumina).

Reads obtained were processed through a bioinformatic pipeline based on iVar⁶⁶, available at https://gitlab.com/fisabio-ngs/sars-cov2-mapping. The first step in the pipeline removed human reads with Kraken⁶⁷; then fastq files were filtered using fastp⁶⁸ v 0.20.1 (arguments employed: --cut tail, --cut-window-size, --cut-mean-quality, -max_len1, -max_len2). Finally, mapping and variant calling were performed with iVar v 1.2, and quality control assessment was carried out with MultiQC⁶⁹.

499 Analysis of the *spike* gene of sarbecoviruses related to SARS-CoV-2

500 14 sequences including SARS-COV-2 belonging to sarbecoviruses, sequences were annotated 501 with annotation files available at NCBI database in order to locate the spike gene coordinates 502 (accession numbers are available at supplemental table 1). For each sequence, nucleotide 503 coordinates belonging to this gene were extracted with EMBOSS⁷⁰. The 14 sequences harbouring 504 the spike gene were concatenated and aligned with MEGA-X⁷¹ using amino acids with ClustalW 505 algorithm with default options (alignment is available at 506 https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2)

507 Sampling SARS-CoV-2 from non-Spanish consortium sequences

508 To build the global alignment, sequences were downloaded from GISAID¹ including all the 509 pandemic periods since the first known case sequenced (from 24 December 2019) until the last 510 sample on 22 December 2020. We used two filters to select the dataset: sequences with more 511 than 29,000 bp, and sequences with known dates of sampling. Sequences downloaded from 512 GISAID were aligned against the SARS-CoV-2 reference genome⁷² using MAFFT⁷³, omitting all 513 insertions and getting an alignment length of 29,903 bp. The final alignment constructed 514 included 270,869 sequences, all sequences with GISAID ID used for this study are available in 515 Supplementary Table 5.

516 Frequency and detection of mutated positions

517 Single nucleotide variants were detected using the global dataset alignment, generating a VCF 518 file with SNP-sites⁷⁴ v 2.5.1 (argument employed: -v), using the reference genome as the 519 reference bases for detecting mutations. This VCF file was processed with a Python script 520 (available at https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2) to assess all 521 mutated samples by position, calculating the frequencies of the global dataset and annotating 522 sequences with the detected mutations. After that, the mutated positions were annotated with 523 snpEff⁷⁵ v 5.0 using SARS-CoV-2 reference (Wuhan first sequenced) database annotation
524 (arguments employed: -c, -noStats, -no-downstream, -no-upstream, NC 045512.2).

525 Genotypes detected that involved mutations in 1163 and 1167 such as B.1.177.637 and cluster 526 163.654 were represented in a circos plot with the R package circlize⁷⁶ v 0.4.12.1004. Nucleotide 527 coordinates of SARS-CoV-2 are plotted in a non-closed circle, circle is annotated and coloured 528 with genes of the virus, and mutated nucleotide positions of each genotype are connected 529 between them through lines.

530 Alignments

For the phylogenetic analysis, a reduced dataset was selected from the 270,869 sequences. Duplicated sequences were removed with seqkit v 0.13.2 (arguments employed: rmdup -s). 8,397 sequences were selected at random with the same temporal distribution by month as the initial dataset by Python scripting (available at https://github.com/PathoGenOmics/ B.1.177.637_SARS-CoV-2). The 8,397 sequences were concatenated with 2,053 sequences selected as indicate above because harboured amino acid replacements in D1163 and G1167 of the S protein and resulted in an alignment of 10,450 sequences (Supplementary Table 6).

The dataset to represent 20I/501Y.V1 phylogenetic relationships include 3,067 randomly selected samples identified by Pangolin typing system (<u>https://github.com/cov-</u> <u>lineages/pangolin</u>) as lineage B.1.1.7 plus the 33 sequences with amino acid replacements in D1163 and/or G1167 (Supplementary Table 7).

542 For all the alignments, problematic positions reported by Lanfear, R.⁷⁷ were masked for the 543 phylogenetic reconstruction using masked_alignment.sh script.

544 **Phylogenetic analysis**

545 Maximum-likelihood phylogenies in Figure 1 and supplementary Supplementary Fig.2, S4 and S5 546 were reconstructed from the masked alignment using IQ-TREE⁷⁸ v 1.6.12 with GTR model and 547 collapsing near-zero branches (arguments employed: -czb, -m GTR). The phylogenies were 548 rooted in the reference sequence from Wuhan⁷² on 2019-12-24. The phylogenies were 549 annotated and visualized with iTOL⁷⁹ v 4.

The phylogeny in Supplementary Video S1, composed by 10,450 sequences, was build up with Nextstrain pipeline (available at <u>https://github.com/nextstrain/augur</u>) in order to monitor and visualize temporal and geographical transmission of B.1.177.637. This dataset file is available at https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2.

554 Clusters of transmission involving 1163 and 1167 S amino acid replacements.

555 We used the phylogeny of 10,450 sequences enriched with all sequences mutated in 1163 and 556 1167 to quantify the minimum number of mutational events involving positions 1163 and 1167 557 in S protein. We first defined which mutations characterize internal nodes using R packages: tidytree v 0.3.3 and treeio v 1.14.3⁸⁰. We then depicted monophyletic clusters sharing at least 558 559 one of the two mutations. Transmission clusters were defined as all sequences that: i) are 560 derived from an internal node characterized by the same nucleotide mutation involving 1163 or 561 1167 amino acid replacements, ii) include more than one sequence, and iii) at least 95% of 562 sequences share the nucleotide mutation. Additionally, redundant nodes were eliminated, 563 keeping the ancestral node of the cluster (harbouring the largest number of leaves). Sequences 564 with at least one mutation but not in clusters were counted as single events of mutation in the 565 phylogeny.

566 Structural analysis of 1163 and 1167 S amino acid replacements.

The atomic coordinates for S protein in pre-fusion state was retrieved from the CHARMM-GUI COVID-19 Archive (http://www.charmm-gui.org/docs/archive/covid19). The atomic coordinates for S protein in post-fusion sate were retrieved from Protein Data Bank (PDB: 6XRA¹⁸ and PDB: 6LXT⁸¹). Mutations were introduced using single mutation tool embedded in COOT⁸² and figures were generated with PyMOL (www.pymol.org).

572 SARS-CoV-2 pseudotyped vesicular stomatitis virus production, titration, and thermal stability 573 evaluation

574 Mutations were introduced into a plasmid encoding a codon-optimized S protein¹⁶ by site 575 directed mutagenesis (see Supplementary table8 for primers). All mutations were verified by 576 Sanger sequencing (see Supplementary table 9 for primers). To evaluate the efficiency of virus 577 production, three transfections in HEK293 cells (CRL-1573 from ATCC) were performed for each 578 plasmid to generate pseudotyped VSV harbouring the indicated S protein⁸³. The titers of the 579 virus produced were then assayed by serial dilution, followed by infection of either Vero cells 580 (CCL-81 from ATCC) or A549 cells expressing ACE2 and TMPRSS2 (InvivoGen catalog code a549-581 hace2tpsa), and counting of GFP positive cells (focus forming units; FFU) at 16 hours post 582 infection. Statistical comparisons were performed by unpaired t-test (R package: stats v 3.6.1) 583 with normalized logarithmic data. For assessing thermal stability, 1000 FFU (as measured on 584 Vero cells) were incubated for 15 minutes at 30.4, 31.4, 33, 35.2, 38.2, 44.8, 47, 48.6 or 49.6°C 585 before addition to Vero cells previously seeded in a 96 well plate (10,000 cells/well). GFP signal 586 in each well was determined 16 hours post-infection using an Incucyte S3 (Essen Biosciences). 587 The mean GFP signal observed in several mock-infected wells was subtracted from all infected 588 wells, followed by standardization of the GFP signal to the mean GFP signal from wells incubated 589 at 30.4°C. Finally, a three parameter log-logistic function was fitted to the data using the drc 590 package v 3.0-1 in R (LL.3 function) and the temperature resulting in 50% inhibition calculated 591 using the drc ED function. Statistical differences in the temperature resulting in 50% reduction

592 of infection was evaluated using the drc EDcomp function. The data and scripts for analysing the 593 temperature resistance of the different mutants is available at 594 https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2.

595 Evaluation of neutralization by convalescent sera and efficacy of virus particle production.

596 Pseudotyped VSV bearing 20E or B.1.177.637 S variants were evaluated for sensitivity to neutralization by convalescent sera as previously described⁸³ with slight modifications. Briefly, 597 598 16-hours post-infection, GFP signal in each well was determined using an Incucyte S3 (Essen 599 Biosciences). The mean GFP signal observed in several mock-infected wells was subtracted from 600 all infected wells, followed by standardization of the GFP signal in each well infected with antibody-treated virus to that of the mean GFP signal from wells infected with mock-treated 601 602 virus. Any negative values resulting from background subtraction were arbitrarily assigned a low, 603 non-zero value (10^{-5}). The serum dilutions were then converted to their reciprocal, their 604 logarithm (Log₁₀) was taken, and the dose resulting in 50% (ID50) or 80% (ID80) reduction in GFP 605 signal was calculated in R using the drc package v 3.0-1. A two-parameter log-logistic regression 606 (LL2 function) was used for all samples except when a three-parameter logistic regression 607 provided a significant improvement to fit, as judged by the ANOVA function in the drc package 608 (e.g. p < 0.05 following multiple testing correction using the Bonferroni method). The script for 609 calculating the ID50 and ID80 as well as the standardized GFP signal for each condition is 610 available at https://github.com/PathoGenOmics/B.1.177.637 SARS-CoV-2. For the first wave, 611 serum samples and data from patients included in this study were provided by the Consorcio 612 Hospital General de Valencia Biobank, integrated in the Valencian Biobanking Network, and they 613 were processed following standard operating procedures with the appropriate approval of the 614 Ethics and Scientific Committees. All first wave samples were obtained from donors that were 615 admitted to the intensive care unit and were collected during April 2020. For the second wave 616 donors, sera were obtained (October 2020) from severe COVID-19 patients requiring inpatient

treatment at Hospital Universitario y Politécnico La Fe de Valencia. Similarly, samples from immunized donors were collected at Hospital Universitario y Politécnico La Fe de Valencia from hospital health-workers, with no previous history of SARS-COV-2 infection, and after receiving a second dose of Pfizer-BioNTech COVID-19 vaccine (BNT162b2; February 2021). All samples from Hospital Universitario y Politécnico La Fe de Valencia were collected after informed written consent and the project has been approved by the ethical committee and institutional review board (registration number 2020-123-1).

624 Acknowledgments

We want to particularly acknowledge the patients and the Consorcio Hospital General de Valencia Biobank integrated in the Valencian Biobanking Network for their collaboration, as well as the patients and hospital staff at Hospital Universitario y Politécnico La Fe de Valencia. In addition, the authors would like to thank Gert Zimmer (Institute of Virology and Immunology, Mittelhäusern/Switzerland), Stefan Pohlmann, and Markus Hoffmann (German Primate Center, Infection Biology Unit, Goettingen/Germany) for providing the reagents required for the generation of VSV pseudotyped viruses and the codon-optimized S plasmid.

Also, we want to acknowledge all the efforts from different laboratories and authorities
submitting all possible sequences of SARS-CoV-2 worldwide and making them available on the
GISAID platform.

635 **Funding**

M.C. and R.G. are supported by Ramón y Cajal program from Ministerio de Ciencia. This work
was funded by the Instituto de Salud Carlos III project COV20/00140 and COV20/00437, Spanish
National Research Council project CSIC-COV19-021 and CSIC-COVID19-082, and the Generalitat
Valenciana (SEJI/2019/011 and Covid_19-SCI).

- 640 Action co-financed by the European Union through the Operational Program of the European
- 641 Regional Development Fund (ERDF) of the Valencian Community 2014-2020.

642 **References**

- 1. Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative
- 644 contribution to global health. *Glob Chall* **1**, 33-46 (2017).
- 645 2. Hadfield, J. *et al.* Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*646 **34**, 4121-4123 (2018).
- 647 3. Lauring, A.S. & Hodcroft, E.B. Genetic Variants of SARS-CoV-2-What Do They Mean?
- 648 Jama **325**, 529-531 (2021).
- 649 4. WHO. COVID-19 Weekly Epidemiological Update 2021-02-25.
- 650 (<u>https://www.who.int/docs/default-source/coronaviruse/situation-</u>
- 651 <u>reports/20210225_weekly_epi_update_voc-special-edition.pdf</u>, 2021).
- 5. Volz, E. *et al.* Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on
- Transmissibility and Pathogenicity. *Cell* **184**, 64-75.e11 (2020).
- 654 6. Hodcroft, E.B. et al. Emergence and spread of a SARS-CoV-2 variant through Europe in
- 655 the summer of 2020. *medRxiv*, 2020.10.25.20219063. Preprint at
- 656 https://www.medrxiv.org/content/10.1101/2020.10.25.20219063v2 (2020).
- 657 7. Oude Munnink, B.B. *et al.* Transmission of SARS-CoV-2 on mink farms between humans
 658 and mink and back to humans. *Science* **371**, 172 (2021).
- 8. Richard, D., Owen, C.J., van Dorp, L. & Balloux, F. No detectable signal for ongoing
- 660 genetic recombination in SARS-CoV-2. *bioRxiv*, 2020.12.15.422866. Preprint at
- 661 https://www.biorxiv.org/content/10.1101/2020.12.15.422866v1 (2020).
- 9. Welkers, M.R.A., Han, A.X., Reusken, C. & Eggink, D. Possible host-adaptation of SARS-
- 663 CoV-2 due to improved ACE2 receptor binding in mink. *Virus Evol* **7**, veaa094 (2021).

- 10. Young, B.E. et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity
- of infection and the inflammatory response: an observational cohort study. *Lancet* **396**, 603-611 (2020).
- 667 11. Chand, M. et al. Investigation of novel SARS-COV-2 variant Variant of Concern
- 668 202012/01. (Public Health England,
- 669 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach
- 670 <u>ment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf</u>, 2020).
- 67112.Walls, A.C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
- 672 Glycoprotein. *Cell* **181**, 281-292.e6 (2020).
- 67313.Salvatori, G. *et al.* SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for
- 674 vaccines. *Journal of Translational Medicine* **18**, 222 (2020).
- Turoňová, B. *et al.* In situ structural analysis of SARS-CoV-2 spike reveals flexibility
 mediated by three hinges. *Science* **370**, 203 (2020).
- 15. Hoffmann, M., Kleine-Weber, H. & Pöhlmann, S. A Multibasic Cleavage Site in the Spike
- 678 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell* **78**, 779-
- 679 784.e5 (2020).
- 680 16. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
- 681 Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8 (2020).
- Kielian, M. Mechanisms of Virus Membrane Fusion Proteins. *Annu Rev Virol* 1, 171-89
 (2014).
- 684 18. Cai, Y. *et al.* Distinct conformational states of SARS-CoV-2 spike protein. *Science* 369,
 685 1586 (2020).
- Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
 Infectivity of the COVID-19 Virus. *Cell* 182, 812-827.e19 (2020).
- Hou, Y.J. *et al.* SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
 transmission in vivo. *Science* **370**, 1464-1468 (2020).

- 690 21. Plante, J.A. *et al.* Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* (2020).
- 691 22. Zhou, B. *et al.* SARS-CoV-2 spike D614G change enhances replication and transmission.
 692 *Nature* (2021).
- 693 23. Daniloski, Z. *et al.* The Spike D614G mutation increases SARS-CoV-2 infection of
 694 multiple human cell types. *Elife* 10(2021).
- 695 24. Larsen, H.D. *et al.* Preliminary report of an outbreak of SARS-CoV-2 in mink and mink
- 696 farmers associated with community spread, Denmark, June to November 2020. *Euro*
- 697 Surveill **26**(2021).
- 698 25. Rodrigues, J. et al. Insights on cross-species transmission of SARS-CoV-2 from
- 699 structural modeling. *PLoS Comput Biol* **16**, e1008449 (2020).
- 700 26. Hodcroft, E.B. CoVariants: SARS-CoV-2 Mutations and Variants of Interest.
- 701 (<u>https://covariants.org/variants/</u>, 2021).
- 702 27. Leung, K., Shum, M.H., Leung, G.M., Lam, T.T. & Wu, J.T. Early transmissibility
- 703 assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom,
- 704 October to November 2020. *Euro Surveill* **26**(2021).
- 705 28. Galloway, S. et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage United States,
- 706 December 29, 2020–January 12, 2021. *MMWR. Morbidity and Mortality Weekly Report* 707 **70**(2021).
- Davies, N.G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7
 in England. *Science*, eabg3055 (2021).
- 710 30. Wang, Z. *et al.* mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating
- 711 variants. *Nature* (2021).
- 712 31. Wibmer, C.K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African
- 713 COVID-19 donor plasma. *bioRxiv*, 2021.01.18.427166. Preprint at
- 714 https://www.biorxiv.org/content/10.1101/2021.01.18.427166v2 (2021).

715	32.	Muik, A. et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2
716		vaccine-elicited human sera. <i>bioRxiv</i> , 2021.01.18.426984. Preprint at
717		https://www.biorxiv.org/content/10.1101/2021.01.18.426984v1 (2021).
718	33.	Madhi, S.A. et al. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19
719		vaccine against the B.1.351 variant in South Africa. <i>medRxiv</i> , 2021.02.10.21251247.
720		Preprint at https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1
721		(2021).
722	34.	Washington, N.L. et al. Genomic epidemiology identifies emergence and rapid
723		transmission of SARS-CoV-2 B.1.1.7 in the United States. medRxiv,
724		2021.02.06.21251159. Preprint at
725		https://www.medrxiv.org/content/10.1101/2021.02.06.21251159v1 (2021).
726	35.	Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory
727		syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in
728		South Africa. medRxiv, 2020.12.21.20248640. Preprint at
729		https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1 (2020).
730	36.	López, M.G. et al. The first wave of the Spanish COVID-19 epidemic was associated
731		with early introductions and fast spread of a dominating genetic variant. medRxiv,
732		2020.12.21.20248328. Preprint at
733		https://www.medrxiv.org/content/10.1101/2020.12.21.20248328v1 (2020) (2020).
734	37.	Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
735		genomic epidemiology. Nature Microbiology 5, 1403-1407 (2020).
736	38.	Nelson, G. et al. Molecular dynamic simulation reveals E484K mutation enhances spike
737		RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations
738		(501Y.V2 variant) induces conformational change greater than N501Y mutant alone,
739		potentially resulting in an escape mutant. <i>bioRxiv</i> , 2021.01.13.426558. Preprint at
740		https://www.biorxiv.org/content/10.1101/2021.01.13.426558v1 (2021).

- 741 39. Liu, Z. et al. Landscape analysis of escape variants identifies SARS-CoV-2 spike
- 742 mutations that attenuate monoclonal and serum antibody neutralization. *bioRxiv*,

743 2020.11.06.372037. Preprint at

- 744 https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2 (2021).
- 745 40. McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of
- 746 vulnerability for SARS-CoV-2. bioRxiv, 2021.01.14.426475. Preprint at
- 747 https://www.biorxiv.org/content/10.1101/2021.01.14.426475v1 (2021).
- 748 41. Huang, Y., Yang, C., Xu, X.-f., Xu, W. & Liu, S.-w. Structural and functional properties of
- 749 SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta
- 750 *Pharmacologica Sinica* **41**, 1141-1149 (2020).
- 751 42. Xia, S. et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1
- 752 domain in spike protein. Cellular & Molecular Immunology 17, 765-767 (2020).
- 753 43. Lu, R. *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus:
- 754 implications for virus origins and receptor binding. *The Lancet* **395**, 565-574 (2020).
- 755 44. Xia, S. et al. Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike 756
- Protein HR1 and HR2 Domains. Int J Mol Sci 19(2018).
- 757 45. Fan, X., Cao, D., Kong, L. & Zhang, X. Cryo-EM analysis of the post-fusion structure of 758 the SARS-CoV spike glycoprotein. Nature Communications 11, 3618 (2020).
- 759 46. Woo, H. et al. Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein 760 Model in a Viral Membrane. The Journal of Physical Chemistry B 124, 7128-7137
- 761 (2020).
- 762 47. Zhang, L. et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike 763 density and infectivity. Nature Communications 11, 6013 (2020).
- 764 48. Yurkovetskiy, L. et al. Structural and Functional Analysis of the D614G SARS-CoV-2

765 Spike Protein Variant. Cell 183, 739-751.e8 (2020).

- Wang, Y. *et al.* The Infectivity and Antigenicity of Epidemic SARS-CoV-2 Variants in the
 United Kingdom. *Research Square* (2021).
- 768 50. Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based bioassay
- 769 for the rapid and sensitive determination of multi-species type I interferon. *PLoS One*
- 770 **6**, e25858 (2011).
- Weissman, D. *et al.* D614G Spike Mutation Increases SARS CoV-2 Susceptibility to
 Neutralization. *Cell Host & Microbe* 29, 23-31.e4 (2021).
- 52. Li, Y. *et al.* Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in
- 774 COVID-19 patients. *Cellular & Molecular Immunology* **17**, 1095-1097 (2020).
- 775 53. Mateus, J. *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed
 776 humans. *Science* **370**, 89-94 (2020).
- Yi, Z. *et al.* Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19
 convalescent population. *Emerg Microbes Infect* **9**, 1988-1996 (2020).
- 779 55. Zhao, J. *et al.* COVID-19: Coronavirus Vaccine Development Updates. *Frontiers in*780 *Immunology* 11, 3435 (2020).
- 78156.Izda, V., Jeffries, M.A. & Sawalha, A.H. COVID-19: A review of therapeutic strategies
- and vaccine candidates. *Clinical Immunology* **222**, 108634 (2021).
- 783 57. Pond, S. Natural selection analysis of global SARS-CoV-2/COVID-19 enabled by data
- 784 from GISAID. (<u>https://observablehq.com/@spond/revised-sars-cov-2-analytics-</u>
- 785 page?collection=@spond/sars-cov-2).
- Wang, S. *et al.* AXL is a candidate receptor for SARS-CoV-2 that promotes infection of
 pulmonary and bronchial epithelial cells. *Cell Research* **31**, 126-140 (2021).
- 788 59. Vita, R. *et al.* The immune epitope database (IEDB) 3.0. *Nucleic Acids Research* **43**,
- 789 D405-D412 (2015).

790	60.	Tarke, A. et al. Comprehensive analysis of T cell immunodominance and
791		immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Reports Medicine
792		2 , 100204 (2021).
793	61.	Kemp, S.A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature
794		(2021).
795	62.	Collier, D.A. et al. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited,
796		convalescent and monoclonal antibodies. medRxiv, 2021.01.19.21249840. Preprint at
797		https://www.medrxiv.org/content/10.1101/2021.01.19.21249840v4 (2021).
798	63.	Wang, P. et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
799		<i>bioRxiv</i> , 2021.01.25.428137. Preprint at
800		https://www.biorxiv.org/content/10.1101/2021.01.25.428137v2 (2021).
801	64.	Quick, J. nCoV-2019 sequencing protocol. (<u>https://www.protocols.io/view/ncov-2019-</u>
802		sequencing-protocol-bbmuik6w.pdf, 2020).
803	65.	Artic-network/artic-ncov2019. (Artic-network, <u>https://github.com/artic-network/artic-</u>
804		<u>ncov2019</u> , 2020).
805	66.	Grubaugh, N.D. et al. An amplicon-based sequencing framework for accurately
806		measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol 20, 8 (2019).
807	67.	Wood, D.E. & Salzberg, S.L. Kraken: ultrafast metagenomic sequence classification
808		using exact alignments. Genome Biol 15, R46 (2014).
809	68.	Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
810		<i>Bioinformatics</i> 34 , i884-i890 (2018).
811	69.	Ewels, P., Magnusson, M., Lundin, S. & Käller, M. MultiQC: summarize analysis results
812		for multiple tools and samples in a single report. <i>Bioinformatics</i> 32 , 3047-8 (2016).
813	70.	Rice, P., Longden, I. & Bleasby, A. EMBOSS: The European molecular biology open
814		software suite. Trends in Genetics 16, 276-277 (2000).

815	71.	Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: Molecular Evolutionary
816		Genetics Analysis across Computing Platforms. Mol Biol Evol 35, 1547-1549 (2018).
817	72.	Wu, F. et al. A new coronavirus associated with human respiratory disease in China.
818		Nature 579 , 265-269 (2020).
819	73.	Katoh, K., Misawa, K., Kuma, K. & Miyata, T. MAFFT: a novel method for rapid multiple
820		sequence alignment based on fast Fourier transform. Nucleic Acids Res 30, 3059-66
821		(2002).
822	74.	Page, A.J. et al. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA
823		alignments. Microb Genom 2, e000056 (2016).
824	75.	Cingolani, P. et al. A program for annotating and predicting the effects of single
825		nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster
826		strain w1118; iso-2; iso-3. Fly 6, 80-92 (2012).
827	76.	Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize implements and enhances
828		circular visualization in R. Bioinformatics 30, 2811-2812 (2014).
829	77.	Lanfear, R. A global phylogeny of SARS-CoV-2 sequences from GISAID. (Zenodo, 2020).
830	78.	Nguyen, L.T., Schmidt, H.A., von Haeseler, A. & Minh, B.Q. IQ-TREE: a fast and effective
831		stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol 32,
832		268-74 (2015).
833	79.	Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v4: recent updates and new
834		developments. Nucleic Acids Research 47, W256-W259 (2019).
835	80.	Wang, L.G. et al. Treeio: An R Package for Phylogenetic Tree Input and Output with
836		Richly Annotated and Associated Data. Mol Biol Evol 37, 599-603 (2020).
837	81.	Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly
838		potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high
839		capacity to mediate membrane fusion. Cell Research 30 , 343-355 (2020).

- 840 82. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot.
- 841 Acta Crystallogr D Biol Crystallogr 66, 486-501 (2010).
- 842 83. Gozalbo-Rovira, R. et al. SARS-CoV-2 antibodies, serum inflammatory biomarkers and
- clinical severity of hospitalized COVID-19 patients. *J Clin Virol* **131**, 104611 (2020).

844 Author contributions

- 845 PRR: Conceptualization, Methodology, Formal Analysis, Investigation, Visualization, Writing
- 846 Original Draft.
- 847 CFG: Conceptualization, Methodology, Formal Analysis, Writing Original Draft.
- 848 ACO: Formal Analysis, Review and edit draft.
- 849 MGL: Formal Analysis, Review and edit draft.
- 850 SJS: Software, Validation, Review and edit draft.
- 851 ICM: Methodology, Resources, Review and edit draft.
- 852 PRH: Investigation, Review and edit draft.
- 853 MTP: Methodology, Resources, Review and edit draft.
- 854 MAB: Investigation, Methodology, Review and edit draft.
- 855 GD: Methodology, Software, Data Curation, Review and edit draft.
- 856 LLM: Methodology, Project Administration, Review and edit draft.
- 857 MG: Resources, Review and edit draft.
- 858 MMA: Resources, Review and edit draft.
- 859 MDG: Resources, Review and edit draft.
- 860 JLP: Resources, Review and edit draft.

- 861 FG: Funding, Project Administration, Supervision, Review and edit draft.
- 862 IC: Funding, Project Administration, Supervision, Review and edit draft.
- 863 AM: Formal analysis, Writing Original Draft.
- RG: Conceptualization, Methodology, Formal Analysis, Writing Original Draft, Supervision,
 Funding.
- MC: Conceptualization, Methodology, Investigation, Formal Analysis, Writing Original Draft,
 Supervision, Funding.

868 List of SeqCOVID consortium members

869 Iñaki Comas (icomas@ibv.csic.es), Fernando González-Candelas (fernando.gonzalez@uv.es), 870 Galo A. Goig-Serrano (ggoig@ibv.csic.es), Álvaro Chiner-Oms (achiner@ibv.csic.es), Irving 871 Cancino-Muñoz (icancino@ibv.csic.es), Mariana Gabriela López (mglopez@ibv.csic.es), Manoli 872 Torres-Puente (mtorres@ibv.csic.es), Inmaculada Gómez (igomez@ibv.csic.es), Santiago 873 Jiménez-Serrano (sjimenez@ibv.csic.es), Lidia Ruiz-Roldán (lidiarroldan@gmail.com), María 874 Alma Bracho (bracho_alm@gva.es), Neris García-González (neris@uv.es), Llúcia Martínez Priego 875 (martinez_lucpri@gva.es), Inmaculada Galán-Vendrell (galan_inm@gva.es), Paula Ruiz-Hueso 876 (ruiz_pau@gva.es), Griselda De Marco (demarco_gri@gva.es), Mª Loreto Ferrús Abad 877 (ferrus_mlo@gva.es), Sandra Carbó-Ramírez (carbo_sanram@gva.es), Mireia Coscollá 878 (mireia.coscolla@uv.es), Paula Ruiz Rodríguez (ruizro5@alumni.uv.es), Giuseppe D'Auria 879 (dauria_giu@gva.es), Francisco Javier Roig Sena (roig_fco@gva.es), Hermelinda Vanaclocha 880 Luna (vanaclocha_her@gva.es), Isabel San Martín Bastida (isanmartin@rjb.csic.es), Daniel 881 García Souto (danielgarciasouto@gmail.com), Ana Pequeño Valtierra (ana.pequeno@usc.es), 882 Jose M. C. Tubio (jmctubio@gmail.com), Fco. Javier Temes Rodríguez (fjtemes@gmail.com), 883 Jorge Rodríguez-Castro (jorge.rodriguez@usc.es), Martín Santamarina García 884 (martin.santamarina.garcia@usc.es), Nuria Rabella Garcia (nrabella@santpau.cat), Ferrán

885 Navarro Risueño (fnavarror@santpau.cat), Elisenda Miró Cardona (emiro@santpau.cat), 886 Manuel Rodríguez-Iglesias (manuel.rodrigueziglesias@uca.es), Fátima Galán-Sanchez 887 (fatima.galan@uca.es), Salud Rodríguez-Pallares (salud361@gmail.com), María de Toro 888 (mthernando@riojasalud.es), María Pilar Bea-Escudero (mpbea@riojasalud.es), José Manuel 889 Azcona-Gutiérrez (jmazcona@riojasalud.es), Miriam Blasco-Alberdi (mblasco@riojasalud.es), 890 Alfredo Mayor (alfredo.mayor@isglobal.org), Alberto L. García-Basteiro (alberto.garcia-891 basteiro@isglobal.org), Gemma Moncunill (gemma.moncunill@isglobal.org), Carlota Dobaño 892 (carlota.dobano@isglobal.org), Pau Cisteró (pau.cistero@isglobal.org), Oriol Mitjà 893 (omitja@flsida.org), Camila González-Beiras (cgonzalez@flsida.org), Martí Vall-Mayans 894 (mvall@flsida.org), Marc Corbacho-Monné (mcorbacho@flsida.org), Andrea Alemany 895 (ealemany@gmail.com), Darío García de Viedma (dgviedma2@gmail.com), Laura Pérez-Lago 896 (lperezg00@gmail.com), Marta Herranz (m_herranz01@hotmail.com), Jon Sicilia 897 (jsiciliamambrilla@gmail.com), Pilar Catalán (pcatalan.hgugm@salud.madrid.org), Julia Suárez 898 (julia.suarez@iisgm.com), Patricia Muñoz (pmunoz@hggm.es), Cristina Muñoz-Cuevas 899 (cristina.munozc@salud-juntaex.es), Guadalupe Rodríguez Rodríguez 900 (guadalupe.rodriguez@salud-juntaex.es), Juan Alberola Enguídanos (juan.alberola@uv.es), Jose 901 Miguel Nogueira Coito (Jose.M.Nogueira@uv.es), Juan José Camarena Miñana 902 (juan.camarena@uv.es), Antonio Rezusta López (arezusta@unizar.es), Alexander Tristancho 903 Baró (aitristancho@salud.aragon.es), Ana Milagro Beamonte (amilagro@salud.aragon.es), 904 Nieves Martínez Cameo (nmcameo@gmail.com), Yolanda Gracia Grataloup 905 (ygrataloup@yahoo.es), Elisa Martró (emartro@igtp.cat), Antoni E. Bordoy (aescalas@igtp.cat), 906 Anna Not (anot@igtp.cat), Adrián Antuori (adrian.antuori@gmail.com), Anabel Fernández 907 (afernandezn.ics@gencat.cat), Nona Romaní (nonaromani@gmail.com), Rafael Benito Ruesca 908 (rbenito@unizar.es), Sonia Algarate Cajo (sonialgarate@gmail.com), Jessica Bueno Sancho 909 (jbuenosan@salud.aragon.es), Jose Luis del Pozo (jdelpozo@unav.es), Jose Antonio Boga Riveiro 910 (joseantonio.boga@sespa.es), Cristián Castelló Abietar (crcaab@hotmail.com), Susana Rojo

911 Alba (ssnrj4@gmail.com), Marta Elena Álvarez Argüelles (martaealvarez@gmail.com), Santiago 912 Melón García (santiago.melon@sespa.es), Maitane Aranzamendi Zaldumbide 913 Óscar (maitane.aranzamendizaldumbide@osakidetza.eus), Martínez Expósito 914 ("OSCAR.MARTINEZEXPOSITO@osakidetza.eus"), Mikel Gallego Rodrigo 915 ("MIKEL.GALLEGORODRIGO@osakidetza.eus"), Maialen Larrea Ayo 916 ("MAIALEN.LARREAAYO@osakidetza.eus"), Nerea Antona Urieta 917 ("NEREA.ANTONAURIETA@osakidetza.eus"), Andrea Vergara Gómez (vergara@clinic.cat), 918 Miguel J Martínez Yoldi (myoldi@clinic.cat), Jordi Vila Estapé (jvila@clinic.cat), Elisa Rubio García 919 (elrubio@clinic.cat), Aida Peiró-Mestres (aida.peiro@isglobal.org), Jessica Navero-Castillejos 920 (jessica.navero@isglobal.org), David Posada (dposada@uvigo.es), Diana Valverde 921 (dianaval@uvigo.es), Estévez (nuestevez@uvigo.es), Fernández-Silva Nuria Iria 922 (irfernandez@uvigo.es), Loretta de Chiara (Ldechiara@uvigo.es), Pilar Gallego 923 (mgallego@alumnos.uvigo.es), Nair Varela (nvarela@alumnos.uvigo.es), Rosario Moreno 924 Muñoz (moreno_rosmuny@gva.es), Mª Dolores Tirado Balaguer (tirado_dolbal@gva.es), Ulises 925 Gómez-Pinedo (ulisesalfonso.gomez@salud.madrid.org), Gozalo Mónica Margüello 926 (monica.gozalo@scsalud.es), Mª Eliecer Cano García (meliecer.cano@scsalud.es), José Manuel 927 Méndez Legaza (josemanuel.mendez@scsalud.es), Jesús Rodríguez Lozano 928 (jesus.rodriguez@scsalud.es), María Siller Ruiz (maria.siller@scsalud.es), Daniel Pablo Marcos 929 (daniel.pablo@scsalud.es), Antonio Oliver (antonio.oliver@ssib.es), Jordi Reina (jorge.reina@ssib.es), Carla López-Causapé (carla.lopez@ssib.es), Andrés Canut Blasco 930 931 (andres.canutblasco@osakidetza.eus), Hernáez Silvia Crespo 932 (silvia.hernaezcrespo@osakidetza.eus), Mª Cordón Rodríguez Luz 933 (marialuzalbina.cordonrodriguez@osakidetza.eus), Mª Concepción Lecaroz Agara 934 (mariaconcepcion.lecarozagara@osakidetza.eus), Carmen Gómez González 935 (carmen.gomezgonzalez@osakidetza.eus), Amaia Aguirre Quiñonero 936 (amaia.aguirrequiñonero@osakidetza.eus), José Israel López Mirones

937 (joseisrael.lopezmirones@osakidetza.eus), Marina Fernández Torres 938 (marina.fernandeztorres@osakidetza.eus), Mª Rosario Almela Ferrer 939 (mariadelrosario.almelaferrer@osakidetza.eus), José Antonio Lepe Jiménez 940 (josea.lepe.sspa@juntadeandalucia.es), Verónica González Galán 941 (veronica.gonzalez.galan.sspa@juntadeandalucia.es), Ángel Rodríguez Villodres 942 (angel.rodriguez.villodres.sspa@juntadeandalucia.es), Nieves Gonzalo Jiménez 943 (gonzalo nie@gva.es), Mª Montserrat Ruiz García (ruiz mongar@gva.es), Antonio Galiana 944 Cabrera (antoniogaliana1@gmail.com), Judith Sánchez-Almendro (judhsa@gmail.com), Gustavo 945 Cilla Eguiluz (CARLOSGUSTAVOSANTIAGO.CILLAEGUILUZ@osakidetza.eus), Milagrosa Montes 946 (MARIAMILAGROSA.MONTESROS@osakidetza.eus), Ros Luis Piñeiro Vázquez 947 (LUISDARIO.PINEIROVAZQUEZ@osakidetza.eus), Sorrarain Ane 948 (ane.sorarrain@biodonostia.org), José María Marimón Ortiz de Zarate 949 (JOSEMARIA.MARIMONORTIZDEZ@osakidetza.eus), Mª Dolores Gómez Ruiz, 950 (gomez.mdo@gmail.com), Eva González Barberá (gonzalez_evabar@gva.es), José Luis López 951 Hontangas (lopez_jlu@gva.es), María Navarro-Marí José 952 (josem.navarro.sspa@juntadeandalucia.es), Pedrosa Corral Irene 953 (irene.pedrosa.sspa@juntadeandalucia.es), Sara Sanbonmatsu Gámez 954 (saral.sanbonmatsu.sspa@juntadeandalucia.es), M. Carmen Perez Gonzalez 955 (mcpergon@gobiernodecanarias.org), Francisco Javier Chamizo López 956 (fchalop@gobiernodecanarias.org), Ana Bordes Benítez (aborben@gobiernodecanarias.org), 957 David Navarro Ortega (david.navarro@uv.es), Eliseo Albert Vicent (eliseo.al.vi@gmail.com), 958 Ignacio Torres (nachotfink@gmail.com), Mª Isabel Gascón Ros (gascon isa@gva.es), Cristina 959 Torregrosa Hetland (cjtorregrosahetland@hotmail.com), Eva Pastor Boix (pastor_eva@gva.es), 960 (cascales pal@gva.es), Paloma Cascales Ramos Begoña Fuster Escrivá (begona.fuster@gmail.com), Concepción Gimeno Cardona (concepcion.gimeno@uv.es), María 961 962 Dolores Ocete Mochón (ocete_mar@gva.es), Rafael Medina González

963 (rafa.medina.gonzalez@gmail.com), Julia González Cantó (juliagonzalez1992@hotmail.com), 964 Olalla Martínez Macias (martinez ola@gva.es), Begoña Palop Borrás (bpalop@hotmail.com), 965 Inmaculada de Toro Peinado (inmadetoro@yahoo.es), Mª Concepción Mediavilla Gradolph 966 (gradolphilla@hotmail.com), Mercedes Pérez Ruiz 967 (mercedes.perez.ruiz.sspa@juntadeandalucia.es), Oscar González-Recio 968 (gonzalez.oscar@inia.es), Mónica Gutiérrez-Rivas (mgrivas9@gmail.com), Encarnación Simarro Córdoba (mesimarro@sescam.jccm.es), Julia Lozano Serra (jlozanos@sescam.jccm.es), Lorena 969 970 Robles Fonseca (Irobles@sescam.jccm.es), Adolfo de Salazar (adolsalazar@gmail.com), Laura 971 Viñuela (lauravinuelagon@gmail.com), Natalia Chueca (naisses@yahoo.es), Federico García 972 (fegarcia@ugr.es), Cristina Gomez-Camarasa (gomezcamarasa@gmail.com), Ana Carvajal 973 (ana.carvajal@unileon.es), Vicente Martín (vicente.martin@unileon.es), Juan Fregeneda 974 (juan.fregeneda@unileon.es), Antonio J. Molina (ajmolt@unileon.es), Héctor Arguello 975 (hector.arguello@unileon.es), Tania Fernandez-Villa (tferv@unileon.es), Amparo Farga Martí 976 (farga_amp@gva.es), Rocío Falcón (falcon_roc@gva.es), Victoria Domínguez Márquez 977 (m.victoria.dominguez@uv.es), José Javier Costa Alcalde (jose.javier.costa.alcalde@sergas.es), 978 Rocío Pena (rocio.trastoy.pena@sergas.es), Trastoy Gema Barbeito Castiñeiras 979 (gema.barbeito.castineiras@sergas.es), Amparo Coira Nieto (amparo.coira.nieto@sergas.es), María Luisa Pérez del Molino Bernal (maria.luisa.perez.del.molino.bernal@sergas.es), Antonio 980 981 Aguilera (antonio.aguilera.guirao@sergas.es), Anna M. Planas (anna.planas@iibb.csic.es), Álex 982 Soriano (asoriano@clinic.cat), Israel Fernández-Cádenas (israelcadenas@yahoo.es), Jordi Pérez-983 Tur (jpereztur@ibv.csic.es), M^a Ángeles Marcos Maeso (mmarcos@clinic.cat), Carmen Ezpeleta 984 Baquedano (cezpeleb@navarra.es), Ana Navascués Ortega (ana.navascues.ortega@navarra.es), 985 Ana Miqueleiz Zapatero (ana.miqueleiz.zapatero@navarra.es), Manuel Segovia Hernández 986 (msegovia@um.es), Antonio Moreno Docón (a.moreno@um.es), Esther Viedma Moreno 987 (ester.viedma@salud.madrid.org), Jesús Mingorance (jesus.mingorance@idipaz.es), Juan Carlos 988 Galán Montemayor (juancarlos.galan@salud.madrid.org), lván Sanz Muñoz

989 (isanzm@saludcastillayleon.es), Diana Pérez San José (dianaperezsj@gmail.com), Maria Gil 990 Fortuño (gil marfor@gva.es), Juan B. Bellido Blasco (bellido jua@gva.es), Alberto Yagüe Muñoz 991 (yague_alb@gva.es), Noelia Henández Pérez (hernandez_noeper@gva.es), Helena Buj Jordá 992 (helenitabuj@hotmail.com), Óscar Pérez Olaso (perez_oscola@gva.es), Alejandro González 993 Praetorius (agonzalezp@sescam.jccm.es), Aida Esperanza Ramírez Marinero 994 (aramirezm@lrc.cat), Eduardo Padilla León (epadillal@lrc.cat), Alba Vilas Basil (avilasb@lrc.cat), 995 Mireia Canal Aranda (mcanala@Irc.cat), Albert Bernet Sánchez (abernet.lleida.ics@gencat.cat), 996 Alba Bellés Bellés (abelles.lleida.ics@gencat.cat), Eric López González 997 (elopezg.lleida.ics@gencat.cat), Iván Prats Sánchez (iprats@gss.cat), Mercè García González 998 (mgarciag.lleida.ics@gencat.cat), Miguel Martínez Lirola 999 (miguelj.martinez.lirola.sspa@juntadeandalucia.es), Maripaz Ventero Martín 1000 (ventero_marmar@gva.es), Carmen Molina Pardines (molina_carpar@gva.es), Nieves Orta Mira 1001 (orta nie@gva.es), María Navarro Cots (navarro dia@gva.es), Inmaculada Vidal Catalá 1002 (vidal_inm@gva.es), Isabel García Nava (garcianava@hotmail.com), Soledad Illescas Fernández-1003 Bermejo (msillescasf@sescam.jccm.es), José Martínez-Alarcón (jmalarcon@sescam.jccm.es), 1004 Marta Torres-Narbona (mtorresn@sescam.jccm.es), Cristina Colmenarejo 1005 (ccolmenarejo@sescam.jccm.es), Lidia García-Agudo (lgagudo@sescam.jccm.es), Jorge Alfredo 1006 Pérez García (jorgep@sescam.jccm.es), Martín Yago López (yago_mar@gva.es), María Ángeles 1007 Goberna Bravo (mariangoberna@gmail.com), Carolina Pla Cortes (caly.cortes@gmail.com), 1008 Noelia Lozano Rodríguez (lozano_noe@gva.es), Nieves Aparici Valero (aparici_nie@gva.es), 1009 Sandra Moreno Marro (moreno_sanmar@gva.es), Agustín Irazo Tatay (iranzo_agu@gva.es), 1010 Isabel Mariscal Pieper (mariscal isa@gva.es), Mª Pilar Ramos (ramos marrei@gva.es), Mónica 1011 Parra Grande (parra_mongra@gva.es), Bárbara Gómez Alonso (gomez_baralo@gva.es), 1012 Francisco José Arjona Zaragozí (arjona fra@gva.es), Amparo Broseta Tamarit 1013 (amparo2400@gmail.com), Juan José Badiola Díez (badiola@unizar.es), Alicia Otero García 1014 (aliciaogar@unizar.es), Eloísa Sevilla Romeo (esevillr@unizar.es), Belén Marín González

1015 (belenm@unizar.es), Mirta García Martínez (gmmirta@hotmail.com), Marina Betancor Caro
1016 (mbetancorcaro@gmail.com), Diego Sola Fraca (diegosola95@gmail.com), Sonia Pérez Lázaro
1017 (soniperez97@gmail.com), Eva Monleón Moscardó (emonleon@unizar.es), Marta Monzón
1018 Garcés (mmonzon@unizar.es), Cristina Acín Tresaco (crisacin@unizar.es), Rosa Bolea Bailo
1019 (rbolea@unizar.es), Bernardino Moreno Burgos (bmoreno@unizar.es), Amparo Broseta Tamarit

1020 (abroseta@hospitalmanises.es), Carlos Gulin Blanco (cgulin@hospitalmanises.es)

1021 Supplementary Material

Supplementary video 1. Geographical transmission of B.1.177.637 visualized with Nextstrain
build.

1024 Supplementary Tables

1031

- 1025 **Supplementary table 1.** Accession numbers for analysed sarbecoviruses.
- 1026 **Supplementary table 2.** Defining SNPs for B.1.177.637, B.1.177.637.V2, and VOI1163.654.
- 1027 Supplementary table 3. Accession numbers of sequences of interest for mutated amino acids
- 1028 484, 501, 1163 and 1167 of the S protein.
- Supplementary table 4. Accession numbers of 5,017 Spanish sequences from SeqCOVID-SPAIN
 consortium.

Supplementary table 5. Accession numbers of 270,869 analysed sequences.

- 1032 **Supplementary table 6.** Accession numbers of 10,450 analysed sequences.
- 1033 **Supplementary table 7.** Accession numbers of 3,067 analysed sequences belonging to 201/501Y.V1.

1035 Supplementary table 8. Primers for site directed mutagenesis of plasmid encoding codon-1036 optimized S protein.

1037 **Supplementary table 9.** Primers for sanger sequencing to detect mutations of interest.

1038 Supplementary Figures

Supplementary Figure 1. Temporal distribution of mutated samples coloured by region. a.
 Distribution of S protein amino acid replacement D1163Y over the pandemic (N=1874). b.
 Distribution of S protein amino acid replacement G1167V over time (N=1708).

Supplementary Figure 2. Maximum-likelihood phylogenies for different PANGO lineages. a.
Complete phylogeny coloured by the PANGO lineages. b. Phylogeny of B.53 lineage. The circle
represents sequences with D1163 amino acid replacement. c. Phylogeny of B.53 lineage. The
inner circle represents sequences with D1163 amino acid replacements, and the external circle
represents sequences with G1167 amino acid replacements. d. Phylogeny of A lineage. The circle

1047 represents sequences with D1163 amino acid replacements. e. Phylogeny of B.1 and derived 1048 lineages. The inner circle represents sequences with D1163 amino acid replacements, and the 1049 external circle represents sequences with G1167 amino acid replacements. f. Phylogeny of B.1.1 1050 and derivative D.1 lineages. The inner circle represents sequences with D1163 amino acid 1051 replacements, and the external circle represents sequences with G1167 amino acid 1052 replacements. g. Phylogeny of B.1.177 and B.1.177.637 lineages. The inner circle represents 1053 sequences with D1163 amino acid replacements, and the external circle represents sequences 1054 with G1167 amino acid replacements. The scale bar of each indicates the number of nucleotide 1055 substitutions per site. The legend of positions 1163 and 1167 is common for all represented 1056 panels.

Supplementary Figure 3. Whole genome mutated positions in genotypes with changes 1163Y
 and 1167V of the S protein. B.1.177.637 is coloured in magenta and cluster 1163.654 is coloured

in orange. Other less frequent genotypes (found in at least 20 sequences) that include changes
in S position 1163 and/or 1167 are coloured in turquoise. Cluster 1163.654 is coloured in navy
blue. Line width is proportional to the frequency of the genotype. Sites 1163 and 1167 in the S
protein are indicated by magenta star symbols, and position 484 in S, whose mutations are
associated with antigenicity changes, is indicated by a navy blue star.

Supplementary Figure 4. Maximum-likelihood phylogeny of 3,067 genomes belonging to 20I/501Y.V1, rooted with Wuhan reference sequence. Mutated sequences with 1163 and/or 1167 amino acids of the S protein are coloured in the circle. The scale bar indicates the number of nucleotide substitutions per site. The biggest clades are collapsed with isosceles triangles.

Supplementary Figure 5. Maximum-likelihood phylogeny of 3,266 SARS-CoV-2 genomes representing 20E clade rooted with Wuhan reference sequence. Sequences from B.1.177.637 are coloured in magenta, sequences not identified as B.1.177.637 are coloured in green, and cluster B.1.177.637.V2 (S protein amino acid replacements: A222V, D614G, E484K, D1163Y, and 141-144Del) is coloured in blue. The scale bar indicates the number of nucleotide substitutions per site. The biggest clades are collapsed, represented as isosceles triangles.

1074 Supplementary Figure 6. Neutralization of the different mutated S protein variants by 1075 convalescent sera from six individuals infected during the first epidemic wave. The reciprocal 1076 titer at which each of the different convalescent sera neutralizes the different variants by 50% 1077 is indicated. Plotted are the mean and standard error of (n=3).

























 Serum 11
 Serum 12
 Serum 13

 Image: Contract of the serum 12
 Image: Contract of the serum 13
 Image: Contract of the serum 13



Reciprocal ID₈₀ Titer (Log₁₀) 3.22 3.22 3.52 \bot Ŧ 3.00 4222 D614G_D11632_G11670 + ^{4222V_D614G_D1163Y_G1167V} 4222V_D614G_D1163Y_G1167V] ^{4222V_D614G_D1163Y_G1167V}] A2221_D614G 42221_D614G 42221_D614G 42221_D614G